PHAXIAM Therapeutics Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Thibaut Fayet

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	less than a year
CEO ownership	n/a
Management average tenure	less than a year
Board average tenure	10.9yrs

Recent management updates

Recent updates

CEO

Thibaut Fayet (55 yo)

less than a year

Tenure

Mr. Thibaut du Fayet serves as Chief Executive Officer at PHAXIAM Therapeutics S.A. since June 23, 2023. He served as Chief Operating Officer and served as Member of the Executive Board at Pherecydes Pharm...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Eric Soyer	Deputy CEO	8.6yrs	€379.72k	0.010% € 1.8k
Jérôme Bailly	Deputy CEO	4.3yrs	€247.91k	0.0063% € 1.1k
Thibaut Fayet	Chief Executive Officer	less than a year	no data	no data
Céline Breda	Chief Technology Officer	less than a year	no data	no data
Cindy Fevre	Chief Scientific Officer	1.3yrs	no data	no data
Naomi Eichenbaum	Director Investor Relations	no data	no data	no data
Anne-Cécile Fumey	Vice President of Human Resources	8.2yrs	no data	0.0014% € 254.9
Karine Charton	Chief Business Officer	less than a year	no data	0.00066% € 118.5
Pascal Birman	Chief Medical Officer	less than a year	no data	no data
Frederique Vieville	Chief Regulatory Officer	less than a year	no data	no data
Philip Lorenzi	Consultant & Member of Scientific Board	no data	no data	no data
Eric Raymond	Consultant & Member of Scientific Board	no data	no data	no data

0.8yrs

Average Tenure

52yo

Average Age

Experienced Management: 0QSS's management team is not considered experienced ( 0.8 years average tenure), which suggests a new team.

Board Members

Name	Position	Tenure	Compensation	Ownership
Philip Lorenzi	Consultant & Member of Scientific Board	14.3yrs	no data	no data
Eric Raymond	Consultant & Member of Scientific Board	14.5yrs	no data	no data
Bridget Bax	Consultant & Member of Scientific Board	12.3yrs	no data	no data
Arthur Frankel	Consultant & Member of Scientific Board	12.3yrs	no data	no data
Kurt Gunter	Consultant & Member of Scientific Board	12.3yrs	no data	no data
Guy Rigaud	Board Censor	no data	no data	no data
Philippe Archinard	Independent Director	10.9yrs	€66.00k	0.017% € 3.0k
Gil Beyen	Vice Chairman	10.9yrs	€572.43k	0.0080% € 1.4k
Hilde Windels	Independent Director	9.6yrs	€51.00k	0.000020% € 3.6
Didier Hoch	Chairman of the Board	less than a year	no data	no data
Leila Nicolas	Representative Director	1.3yrs	no data	no data
Robert Sebbag	Independent Director	less than a year	no data	no data

10.9yrs

Average Tenure

62yo

Average Age

Experienced Board: 0QSS's board of directors are seasoned and experienced ( 10.9 years average tenure).

PHAXIAM Therapeutics Management

Management criteria checks 1/4

Key information

Recent management updates

ERYTECH Pharma S.A Announces Management Changes

Erytech Pharma S.A. Approves the Appointment of Robert Sebbag and Eric Leire as Directors

Insufficient new directors

Insufficient new directors

Insufficient new directors

Insufficient new directors

Recent updates

PHAXIAM Therapeutics Announces Enrolment of First Patient in the Phase 1 Study for the Treatment of Endocarditis Infections Caused by Staphylococcus Aureus

PHAXIAM Therapeutics Announces Intention to Voluntary Delist ADS from Nasdaq Capital Market

PHAXIAM Therapeutics Announces Intention to Voluntary Delist ADS from Nasdaq Capital Market

No longer forecast to breakeven

PHAXIAM Therapeutics S.A. to Report Q3, 2024 Results on Nov 13, 2024

PHAXIAM Therapeutics Obtains Authorizations to Launch Its Phase 1 Study in Endocarditis Infections Caused by Staphylococcus Aureus

New major risk - Revenue and earnings growth

PHAXIAM Therapeutics Announces High Coverage Performance of Its Two Anti-Staphylococcus Aureus Phages over Clinical Strains

PHAXIAM Therapeutics Receives Compliance Notice from Nasdaq

New major risk - Financial position

PHAXIAM Therapeutics S.A. Announces Launch of New Preclinical Development

PHAXIAM Therapeutics S.A. to Report Q2, 2023 Results on Sep 21, 2023

New major risk - Shareholder dilution

ERYTECH Pharma S.A.(NasdaqCM:PHXM) dropped from NASDAQ Composite Index

ERYTECH Pharma S.A Announces Management Changes

Erytech Pharma S.A. Approves the Appointment of Robert Sebbag and Eric Leire as Directors

Akkadian Initiates Proceedings to Postpone the Vote on the Merger with Pherecydes

Mediobanca Banca di Credito Finanziario S.p.A. agreed to acquire an unknown minority stake in Anima Holding S.p.A. from Omnes Capital S.A.S., Auriga Partners, Ace Capital Partners, Go Capital SAS and Participations Besançon.

No longer forecast to breakeven

Insufficient new directors

No longer forecast to breakeven

Insufficient new directors

ERYTECH Announces Receipt of Nasdaq Notice

ERYTECH Pharma S.A. to Report Q3, 2022 Results on Nov 21, 2022

Insufficient new directors

ERYTECH Pharma to Stop Further Plans to Pursue A BLA Submission Seeking an Approval for Graspa® in Hypersensitive ALL

No longer forecast to breakeven

Insufficient new directors

Insufficient new directors

No longer forecast to breakeven

No longer forecast to breakeven

No longer forecast to breakeven

Catalent, Inc. (NYSE:CTLT) acquired Cell therapy manufacturing facility in Princeton, New Jersey of ERYTECH Pharma S.A. (ENXTPA:ERYP) for $44.5 million.

Catalent, Inc. (NYSE:CTLT) entered into an asset purchase agreement to acquire Cell therapy manufacturing facility in Princeton, New Jersey of ERYTECH Pharma S.A. (ENXTPA:ERYP) for $44.5 million.

Catalent, Inc. (NYSE:CTLT) entered into an asset purchase agreement to acquire Cell therapy manufacturing facility in Princeton, New Jersey of ERYTECH Pharma S.A. (ENXTPA:ERYP) for $44.5 million.

ERYTECH Pharma Announces Publication of Positive Results from Eryaspase Phase 2 Trial

ERYTECH Pharma Expands Patent Portfolio for the Treatment of Rare Metabolic Diseases

ERYTECH Pharma Announces Presentation of Results of Two Clinical Trials of Eryaspase in Pancreatic Cancer at ASCO GI

No longer forecast to breakeven

Forecast to breakeven in 2023

Revenue misses expectations

New 90-day low: €6.70

ERYTECH Pharma Announces TRYbeCA-1 Phase 3 Trial in 2L Pancreatic Cancer to Continue to Final Analysis

New 90-day high: €8.80

ERYTECH Pharma Announces First Patient Enrolled in a Phase 1 Investigator Sponsored Trial of Eryaspase in First-Line Pancreatic Cancer

ERYTECH Completes Enrollment in TRYbeCA-1 Phase 3 Trial in Second-Line Pancreatic Cancer

New 90-day high: €8.07

New 90-day high: €6.55

Revenue misses expectations

ERYTECH Pharma S.A. Announces That an Abstract Detailing Results from the NOPHO Sponsored Phase 2 Trial of Eryaspase in All Patients, Has Been Selected for Oral Presentation At the Upcoming 62nd American Society of Hematology (ASH) Annual Meeting

ERYTECH Pharma S.A. to Report Q2, 2021 Results on Sep 20, 2021

ERYTECH Pharma Appoints Stewart Craig as Chief Technical Officer and Member of the Executive Team

CEO

Tenure

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age